PEDAL Study Demonstrates Prospera Kidney Test Accurately Predicts Long-Term Outcomes After Transplant Rejection
核心洞察
The PEDAL study, published in the American Journal of Transplantation, represents the first prospective multi-center trial evaluating donor-derived cell-free DNA trends for post-rejection patient management in kidney transplants.
Results from 66 patients with biopsy-proven acute rejection showed that patients with low/decreasing Prospera (搜索) trends had 60x higher odds of positive outcomes and were 13x more likely to have resolving kidney dysfunction.
Conversely, 97.5% of patients with sustained elevated Prospera (搜索) trends experienced negative clinical outcomes, demonstrating the test's strong prognostic ability.
Natera's Prospera (搜索) kidney transplant monitoring test has demonstrated significant prognostic value in predicting long-term outcomes following rejection episodes, according to results from the landmark PEDAL study published in the American Journal of Transplantation. The prospective multi-center trial represents the first comprehensive evaluation of how donor-derived cell-free DNA (dd-cfDNA) trends can guide post-rejection patient management decisions.
Study Design and Patient Population
The PEDAL study enrolled 488 kidney transplant recipients from 28 participating U.S. and international transplant centers over a four-year period. Among these patients, 66 individuals with biopsy-proven acute rejection (BPAR) underwent longitudinal testing with Prospera (搜索) during the immediate eight-week period following their rejection episode. Clinical outcomes were then tracked and recorded at the 12-month mark.
Key Clinical Findings
The study revealed striking differences in outcomes based on dd-cfDNA trends measured by the Prospera (搜索) test. Patients with low or decreasing Prospera trends demonstrated dramatically better prognosis, with odds of experiencing positive outcomes after one year that were 60 times higher compared to those with elevated trends. These same patients were also 13 times more likely to experience resolving kidney dysfunction.
The predictive power of sustained elevated dd-cfDNA levels proved equally compelling from a negative prognostic standpoint. Among patients with sustained elevated or high Prospera (搜索) trends, 97.5% (40 out of 41 cases) experienced negative clinical outcomes, underscoring the test's ability to identify high-risk patients requiring intensive management.
Clinical Implications for Transplant Management
"Following a rejection episode, understanding the long-term prognosis and risk is critical in making ongoing treatment decisions for the patient," said Suphamai Bunnapradist, M.D., professor of medicine at UCLA and principal investigator of the PEDAL study. "These findings make it clear that dd-cfDNA is an important non-invasive tool to provide more accurate risk stratification post-rejection that will enable more personalized patient management and improve long-term graft survival."
The statistical association between Prospera (搜索) trends and clinical outcomes suggests that dd-cfDNA monitoring could fundamentally change how physicians approach post-rejection care, moving from reactive to predictive management strategies.
Technology and Methodology
The Prospera (搜索) test utilizes Natera's single-nucleotide polymorphism (SNP)-based massively multiplexed PCR technology to measure the fraction of donor-derived cell-free DNA in the recipient's blood. This approach enables non-invasive detection of allograft rejection with high precision and accuracy, without requiring prior donor or recipient genotyping.
"This study, the first prospective, multi-center trial to examine this use case, highlights how dynamic monitoring with Prospera (搜索) provides critical information following a rejection event," said Hossein Tabriziani, M.D., senior medical director of organ health and transplantation at Natera. "By leveraging Prospera, we can empower physicians to make more informed treatment decisions during the immediate post-rejection phase in kidney transplant management."
Broader Impact on Transplant Care
The PEDAL study results position dd-cfDNA monitoring as a potentially transformative tool in transplant medicine, offering clinicians objective, quantitative data to guide treatment intensification or de-escalation decisions. The test's ability to predict long-term outcomes with such precision could help optimize immunosuppressive regimens, reduce unnecessary interventions in low-risk patients, and intensify monitoring in high-risk cases.
The Prospera (搜索) test has been clinically and analytically validated for performance across different donor relationships, rejection types, and clinical presentations, supporting its broad applicability in kidney transplant monitoring protocols.